Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 6/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 4/20 | 0.48 |
| ▸ | HTR1B | P28222 | 3/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26078344 | 0.79 | ADRA1A (0.55) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL26078342 | 0.79 | ADRA1A (0.52) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL24359761 | 0.74 | ADORA2A (0.46) | ADRA1AMAPK1LMNAMAPT | |
| SCHEMBL26078347 | 0.74 | ADRA1A (0.55) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL26078338 | 0.74 | HTR1D (0.49) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL26078320 | 0.74 | ADRA1A (0.52) | ADRA1ATAAR1ADRA2AADRA2BADRA2C | |
| SCHEMBL26078511 | 0.73 | TAAR1 (0.65) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL26078324 | 0.73 | ADRA1A (0.58) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL26078323 | 0.73 | ADRA1A (0.56) | ADRA1ATAAR1MAPK1ADRA2AADRA2B | |
| SCHEMBL26078321 | 0.73 | ADRA1A (0.56) | ADRA1ATAAR1MAPK1ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312524-A1 | ALPHA1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | ADRA1A, ADRB1, ADRA1D | ADRA1A 1/4885TAAR1 26/4885MAPK1 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.